LABS — Medipharm Labs Income Statement
0.000.00%
- CA$30.30m
- CA$15.49m
- CA$33.06m
- 35
- 67
- 79
- 63
Annual income statement for Medipharm Labs, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 129 | 36 | 21.7 | 22.1 | 33.1 |
Cost of Revenue | |||||
Gross Profit | 42.9 | -44 | -15.2 | -1.91 | 3.99 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 122 | 109 | 70.6 | 51.6 | 46.9 |
Operating Profit | 6.94 | -72.6 | -48.9 | -29.5 | -13.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 6.75 | -72.1 | -54.7 | -30 | -13.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.13 | -67.1 | -54.8 | -30 | -13.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1.65 | -66.4 | -54.8 | -30 | -13.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.65 | -66.4 | -54.8 | -30 | -13.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.016 | -0.484 | -0.221 | -0.106 | -0.047 |